3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
Conditions
Gastro-enteropancreatic neuroendocrine tumor
2
Prolactin-Producing Pituitary Tumor
1
Lymphoma, Follicular
1
Interventions
Rituximab
53
Cyclophosphamide
50
Lenalidomide
41
fludarabine
24
obinutuzumab
23
Prednisone
19
Bendamustine Hydrochloride
19
Magnetic Resonance Spectroscopy
18
Vincristine
17
Doxorubicin
16
fludarabine phosphate
15
Specimen Handling
15
zanubrutinib
13
Biopsy
12
tazemetostat
10
ibrutinib
10
Whole-Body Irradiation
10
pembrolizumab
9
Peripheral Blood Stem Cell Transplantation
9
venetoclax
8
Mycophenolic Acid
7
Etoposide
7
axicabtagene ciloleucel
6
Radiotherapy
6
CT-P10
6
Therapeutics
5
R-CHOP protocol
5
tafasitamab
4
polatuzumab vedotin
4
acalabrutinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
pasireotide
×
1 year
×
Clear all
NCT06784752
2026-04-30
NETTER-3
Novartis
Phase 3
Recruiting
240 enrolled